Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Pacira BioSciences's Net Cash per Share or its related term are showing as below:
During the past 13 years, the highest Price-to-Net-Cash Ratio of Pacira BioSciences was 337.11. The lowest was 33.53. And the median was 69.20.
PCRX's Price-to-Net-Cash is not ranked *
in the Drug Manufacturers industry.
Industry Median: 8.675 * Ranked among companies with meaningful Price-to-Net-Cash only.
Pacira BioSciences (NAS:PCRX) Net Cash per Share Explanation
Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.
You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.
Pacira BioSciences Net Cash per Share Related Terms
Pacira BioSciences Net Cash per Share Historical Data
* Premium members only.
The historical data trend for Pacira BioSciences's Net Cash per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PCRX vs ALVO, BIOA, COLL: Net Cash per Share Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Pacira BioSciences's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacira BioSciences Price-to-Net-Cash vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Pacira BioSciences's Price-to-Net-Cash distribution charts can be found below:
* The bar in red indicates where Pacira BioSciences's Price-to-Net-Cash falls into.
In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.
Pacira BioSciences's Net Cash per Share for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacira BioSciences (PCRX) has a Net Cash per Share of $-8.06 as of Jun. 2026. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Pacira BioSciences and its competitors. Over the past decade, Pacira BioSciences' Net Cash per Share has ranged from 33.53 to 337.11. According to the industry distribution chart, Pacira BioSciences ranks #999999 out of 246 companies in the Drug Manufacturers industry.
Is Pacira BioSciences' Net Cash per Share too high?
Pacira BioSciences' current Net Cash per Share is $-8.06. Over the past 10 years, this metric has ranged from a low of 33.53 to a high of 337.11. Based on the distribution chart, Pacira BioSciences ranks #999999 out of 246 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Pacira BioSciences has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pacira BioSciences' Net Cash per Share compare to ALVO and BIOA?
According to the Drug Manufacturers industry distribution chart, Pacira BioSciences ranks #999999 out of 246 companies for Net Cash per Share. This places Pacira BioSciences in the lower half of its industry. The industry median Net Cash per Share is 8.68. Historically, Pacira BioSciences' own Net Cash per Share has ranged from 33.53 to 337.11 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Cash per Share for a Drug Manufacturers company?
The median Net Cash per Share among Drug Manufacturers companies is 8.68, based on 246 companies in the industry. Companies in the top quartile (top 25%) have a Net Cash per Share significantly above this median, while those in the bottom quartile fall well below. However, Net Cash per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Cash per Share mean?
A high Net Cash per Share can signal that a stock is expensive relative to its fundamentals. Net cash per share equals the per-share value of cash and equivalents less total liabilities and minority interest. View historical data on Pacira BioSciences and its competitors. For the Drug Manufacturers industry, the median Net Cash per Share is 8.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacira BioSciences's current Net Cash per Share is $-8.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacira BioSciences stock overvalued right now?
Based on GuruFocus' analysis, Pacira BioSciences (PCRX) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.19, compared to a current price of $24.70 — trading 15.4% below its estimated fair value. The current Net Cash per Share is $-8.06. Pacira BioSciences' overall GF Score™ is 81/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Cash per Share calculated?
Net Cash per Share is calculated from a company's financial statements. For Pacira BioSciences (PCRX), the current Net Cash per Share is $-8.06 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacira BioSciences (PCRX) Overvalued in 2026?
Based on GuruFocus' analysis, Pacira BioSciences stock appears to be undervalued.
The current stock price of $24.70 is trading 15.4% below its estimated GF Value™ of $29.19.
GuruFocus considers Pacira BioSciences to be Modestly Undervalued.
Key valuation signals for PCRX:
Net Cash per Share: $-8.06
GF Value™: $29.19 vs. price of $24.70 (15.4% below fair value)
No single metric tells the full story. See the PCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
81GF Score
Get the complete analysis for PCRX
Net Cash per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCRX has been successfully added to your 
